Swipe om te navigeren naar een ander artikel
Vesnarinone Trial (VesT) was a three-armed, placebo-controlled, randomized clinical trial designed to study the effects of 30 mg or 60 mg/day vesnarinone. Certain contradictory results involving patient health-related quality-of-life (HRQOL) and overall survival (OS) have made a definitive and unified conclusion difficult.
To reconcile these findings, we have focused on the HRQOL-adjusted OS, commonly known as quality-adjusted life years (QALYs). Currently, analyses of QALYs incorporate a single HRQOL subscale. However, the VesT HRQOL instrument had two subscales: physical (PHYS) and emotional (EMOT). We have developed new ways to visualize and compare EMOT- and PHYS-adjusted OS.
In each VesT arm, there was an increased probability of superior EMOT-adjusted OS, compared to PHYS-adjusted OS. The magnitude of these findings was comparable across trial arms. Despite inferior survival and superior EMOT and PHYS scores, the 60-mg/day arm presents similar EMOT- and PHYS-adjusted OS compared to the placebo arm.
We have provided a fresh perspective on the complex interactions between multiple HRQOL dimensions and OS. These novel methods address the burgeoning need for robust information on the interplay between OS and HRQOL from a patient, clinical care and public policy perspective.
Log in om toegang te krijgen
Met onderstaand(e) abonnement(en) heeft u direct toegang:
Spilker, B. (1996). Quality of life and pharmacoeconomics in clinical trials (2nd ed.). New York: Lippincott Williams & Williams.
Ware, J. E., Kosinski, M., Dewey, J. E., & Gandek, B. (2000) . SF-36 health survey: Manual and interpretation guide. Quality Metric Inc. Boston: Health Institute, New England Medical Center, 1993.
Parasuraman, S., Hudes, G., Levy, D., Strahs, A., Moore, L., DeMarinis, R., et al. (2007). Comparison of quality-adjusted survival in patients with advanced renal cell carcinoma receiving first-line treatment with temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of IFN+TEMSR. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition), 25(18S), 5049.
Torrance, G., & Feeny, D. (1989). Utilities and quality-adjusted life years. International Journal of Technology Assessment, 5, 559–575. CrossRef
Goldhirsch, A., Gelber, R., Simes, R., Glasziou, P., & Coates, A. (1989). Costs and benefits of adjuvant therapy in breast cancer: A quality-adjusted survival analysis. Journal of Clinical Oncology, 7, 36–44. PubMed
Gelber, R. D., Cole, B. F., Gelber, S., & Goldhirsch, A. (1995). Comparing treatments using quality-adjusted survival: The Q-TWiST method. American Statistician, 49, 161–169.
Perkins, M., Howard, V., Wadley, V. G., Crowe, M., Safford, M. M., Haley, W. E., et al. (2013). Caregiving strain and all-cause mortality: evidence from the REGARDS study. The Journals of Gerontology Series B: Psychological Sciences and Social Sciences, 68(4), 504–512. CrossRef
Rogers, J. G., Bostic, R. R., Tong, K. B., Adamson, R., Russo, M., & Slaughter, M. S. (2012). Cost-effectiveness analysis of continuous-flow left ventricular assist devices as destination therapy. Circulation: Heart Failure, 5(1), 10–16.
Lin, D. Y., Sun, W., & Ying, Z. (1999). Nonparametric estimation of the gap time distributions for serial events with censored data. Biometrika, 86, 59–70. CrossRef
Zhao, H., & Tsiatis, A. A. (1997). A consistent estimator for the distribution of quality adjusted survival time. Biometrika, 84, 339–348. CrossRef
Gill, R. D. (1983). Large sample behaviour of the product-limit estimator on the whole line. Annals of Statistics, 11, 49–58. CrossRef
Andrei, A. -C., & Murray, S. (2006). Estimating the quality-of-life-adjusted gap time distribution of successive events subject to censoring. Biometrika, 93(2), 343–355. CrossRef
- Visualization and dynamics of multidimensional health-related quality-of-life-adjusted overall survival: a new analytic approach
Kathleen L. Grady
- Springer International Publishing